Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.78
ALIM's Cash to Debt is ranked higher than
56% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.03 vs. ALIM: 1.78 )
Ranked among companies with meaningful Cash to Debt only.
ALIM' s 10-Year Cash to Debt Range
Min: 0.32   Max: N/A
Current: 1.78

Equity to Asset 0.42
ALIM's Equity to Asset is ranked lower than
51% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.43 vs. ALIM: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
ALIM' s 10-Year Equity to Asset Range
Min: -0.25   Max: 0.45
Current: 0.42

-0.25
0.45
F-Score: 3
Z-Score: -2.57
M-Score: -99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -355.13
ALIM's Operating margin (%) is ranked lower than
72% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. ALIM: -355.13 )
Ranked among companies with meaningful Operating margin (%) only.
ALIM' s 10-Year Operating margin (%) Range
Min: -1837.82   Max: -391.16
Current: -355.13

-1837.82
-391.16
Net-margin (%) -242.72
ALIM's Net-margin (%) is ranked lower than
72% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. ALIM: -242.72 )
Ranked among companies with meaningful Net-margin (%) only.
ALIM' s 10-Year Net-margin (%) Range
Min: -2469.5   Max: -426.33
Current: -242.72

-2469.5
-426.33
ROE (%) -101.71
ALIM's ROE (%) is ranked lower than
76% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.48 vs. ALIM: -101.71 )
Ranked among companies with meaningful ROE (%) only.
ALIM' s 10-Year ROE (%) Range
Min: -270.19   Max: -61.59
Current: -101.71

-270.19
-61.59
ROA (%) -31.53
ALIM's ROA (%) is ranked lower than
72% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. ALIM: -31.53 )
Ranked among companies with meaningful ROA (%) only.
ALIM' s 10-Year ROA (%) Range
Min: -329.68   Max: -20.46
Current: -31.53

-329.68
-20.46
ROC (Joel Greenblatt) (%) -1436.89
ALIM's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.04 vs. ALIM: -1436.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALIM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14172.99   Max: -1226.39
Current: -1436.89

-14172.99
-1226.39
EBITDA Growth (3Y)(%) 6.40
ALIM's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -31.90 vs. ALIM: 6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALIM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 13.3
Current: 6.4

0
13.3
EPS Growth (3Y)(%) 8.10
ALIM's EPS Growth (3Y)(%) is ranked higher than
78% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -53.60 vs. ALIM: 8.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALIM' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 19.5
Current: 8.1

0
19.5
» ALIM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ALIM Guru Trades in Q4 2013

Columbia Wanger 3,016,280 sh (unchged)
» More
Q1 2014

ALIM Guru Trades in Q1 2014

Columbia Wanger 3,016,280 sh (unchged)
Columbia Wanger 3,016,280 sh (unchged)
» More
Q2 2014

ALIM Guru Trades in Q2 2014

Columbia Wanger 1,168,298 sh (-61.27%)
» More
Q3 2014

ALIM Guru Trades in Q3 2014

Columbia Wanger Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALIM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 144.93
ALIM's Forward P/E is ranked lower than
51% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 129.87 vs. ALIM: 144.93 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/S 17.90
ALIM's P/S is ranked lower than
107% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALIM: 17.90 )
Ranked among companies with meaningful P/S only.
ALIM' s 10-Year P/S Range
Min: 17.7   Max: 512
Current: 17.9

17.7
512
Current Ratio 5.86
ALIM's Current Ratio is ranked higher than
87% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. ALIM: 5.86 )
Ranked among companies with meaningful Current Ratio only.
ALIM' s 10-Year Current Ratio Range
Min: 0.59   Max: 11.78
Current: 5.86

0.59
11.78
Quick Ratio 5.69
ALIM's Quick Ratio is ranked higher than
88% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. ALIM: 5.69 )
Ranked among companies with meaningful Quick Ratio only.
ALIM' s 10-Year Quick Ratio Range
Min: 0.59   Max: 11.78
Current: 5.69

0.59
11.78
Days Inventory 505.91
ALIM's Days Inventory is ranked lower than
72% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 151.00 vs. ALIM: 505.91 )
Ranked among companies with meaningful Days Inventory only.
ALIM' s 10-Year Days Inventory Range
Min: 245.39   Max: 445.49
Current: 505.91

245.39
445.49
Days Sales Outstanding 121.57
ALIM's Days Sales Outstanding is ranked lower than
55% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.78 vs. ALIM: 121.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALIM' s 10-Year Days Sales Outstanding Range
Min: 36.83   Max: 97.49
Current: 121.57

36.83
97.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 39.50
ALIM's Price/Net Cash is ranked higher than
84% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALIM: 39.50 )
Ranked among companies with meaningful Price/Net Cash only.
ALIM' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 65.75
Current: 39.5

1.37
65.75
Price/Median PS Value 0.50
ALIM's Price/Median PS Value is ranked higher than
96% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. ALIM: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
ALIM' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 12.51
Current: 0.5

0.53
12.51
Earnings Yield (Greenblatt) -15.70
ALIM's Earnings Yield (Greenblatt) is ranked lower than
82% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. ALIM: -15.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ALIM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -16.2   Max: 0
Current: -15.7

-16.2
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ASZ.Germany,
Alimera Sciences Inc is a Delaware corporation incorporated on June 4, 2003. The Company, along with its subsidiaries is engaged in the research, development and commercialization of presecription ophthalmic pharmaceuticals. The Company's commercial product ILUVIEN, was developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can cause severe vision loss and blindness. ILUVIEN has received marketing authorization in the U.S., Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, and the United Kingdom and has been recommended for marketing authorization in Poland. ILUVIEN is an intravitreal implant that treats patients by delivering a consistent sub-microgram daily dose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, which is sustained through 36 months. ILUVIEN is inserted in a non-surgical procedure employing a device with a 25-gauge needle which allows for a self-sealing wound. In approved European countries, the procedure is performed in a hospital or private clinic setting. In the U.S., the non-surgical procedure is performed in the retinal specialist's office. ILUVIEN, which is non-bioerodable, provides consistent delivery as a result of its constant surface area. This provides a sustained therapeutic effect on DME, and an adverse event profile that is predictable and manageable by a retinal physician. The Company relies on its manufacturers to purchase materials from third-party suppliers necessary to produce ILUVIEN. The Company competes with pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. The Company's competitors include Roche, Allergan, Regeneron and Bayer. The Company owns six U.S. utility patents, one U.S. design patent and two U.S. patent applications as well as numerous foreign counterparts to many of these patents and patent applications relating to ILUVIEN or the ILUVIEN applicator. The Company licensed two European patents from pSivida directed to its low-dose device and have an application pending directed to its applicator system for ILUVIEN. The manufacture and packaging of pharmaceutical products such as ILUVIEN and any future product candidates are regulated by the FDA and similar foreign regulatory agencies.
» More Articles for ALIM

Headlines

Articles On GuruFocus.com
comment on ALIM Mar 02 2013 
Alimera Sciences Inc. (ALIM) President and CEO C. Daniel Myers sells 45,523 Shares Mar 16 2011 
The Most Speculative Stocks on the Market: Harbinger, Kaching Kaching, Alimera Sciences, Star Scient Jul 29 2010 

More From Other Websites
ALIMERA SCIENCES INC Financials May 19 2015
Alimera Sciences Announces Presentation Time Change At UBS Global Healthcare Conference May 18 2015
Alimera Sciences Announces Presentation Time Change At UBS Global Healthcare Conference May 18 2015
ALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 18 2015
10-Q for Alimera Sciences, Inc. May 13 2015
Alimera Sciences To Present At UBS Global Healthcare Conference May 11 2015
ALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 11 2015
Alimera Sciences To Present At UBS Global Healthcare Conference May 11 2015
Alimera Sciences reports 1Q loss May 07 2015
Alimera Sciences reports 1Q loss May 07 2015
ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 07 2015
Alimera Sciences Reports First Quarter 2015 Financial Results May 07 2015
Q1 2015 Alimera Sciences Inc Earnings Release - After Market Close May 07 2015
10-K for Alimera Sciences, Inc. May 05 2015
Alimera Sciences to Release First Quarter 2015 Financial Results Apr 28 2015
Alimera Sciences to Release First Quarter 2015 Financial Results Apr 28 2015
Great Point Partners Trims Its Stake In Alcobra Ltd (ADHD) Apr 22 2015
ILUVIEN® Is Now Widely Available To Diabetic Macular Edema Patients Throughout The U.S. Apr 21 2015
ILUVIEN® Is Now Widely Available To Diabetic Macular Edema Patients Throughout The U.S. Apr 21 2015
Alimera Sciences' ILUVIEN® Receives 17th European Marketing Authorization; Completing Second Wave... Apr 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK